Compare HPF & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPF | LFCR |
|---|---|---|
| Founded | 2002 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 296.0M |
| IPO Year | N/A | N/A |
| Metric | HPF | LFCR |
|---|---|---|
| Price | $16.10 | $7.91 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 35.3K | ★ 145.9K |
| Earning Date | 01-01-0001 | 01-02-2026 |
| Dividend Yield | ★ 8.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $128,867,000.00 |
| Revenue This Year | N/A | $2.80 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.47 |
| 52 Week Low | $12.99 | $4.76 |
| 52 Week High | $16.80 | $8.85 |
| Indicator | HPF | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 59.10 |
| Support Level | $16.25 | $7.34 |
| Resistance Level | $16.35 | $7.87 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 2.13 | 90.48 |
John Hancock Preferred Income Fund II is the United States based closed-end, diversified management investment company. Its primary objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. The fund's principal investment strategies include to invests a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, capital preferred securities and short-term investments.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.